| 查看: 456 | 回复: 0 | |||
chao1.zhang银虫 (小有名气)
|
[交流]
罗氏抗体-药物偶合新药上市,又一系列重磅开始?
|
|
Trastuzumab emtansine (INN; in the United States, ado-trastuzumab emtansine, trade name Kadcyla) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1).Trastuzumab alone kills cancer cells by binding to the HER2 receptor. The conjugate includes emtansine, which enters the cell and destroys the cell by binding to tubulin.Because monoclonal antibodies target HER2, and HER2 is only expressed in breast cancer cells, the conjugate delivers the toxin emtansine only to breast cancer cells.Meet the Bay Area's next blockbuster drug: T-DM1, a breast cancer-fighting treatment developed by Genentech Inc., leads the early Class of 2013 drugs seeking Food and Drug Administration approval. The FDA's decision date is Feb. 26. In the EMILIA clinical trial of women with advanced HER2 positive breast cancer who were already resistant to trastuzumab alone, it improved survival by 5.8 months compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. FDA approved marketing on February 22, 2013. |
» 猜你喜欢
克立硼罗
已经有0人回复
米拉贝隆
已经有0人回复
药理学论文润色/翻译怎么收费?
已经有113人回复
SPME-GC-O-MS
已经有0人回复
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
求助https://www.pnas.org/doi/10.1073/pnas.2535777123 全文
已经有0人回复
祈福面上能中
已经有141人回复
求Endnote官网关于《Avian Conservation and Ecology》杂志的.ens文件
已经有2人回复
【2027申博自荐】9篇SCI+国奖 | 水凝胶/纳米酶/生物材料 | 求博导带走
已经有1人回复
27年药学 考博申请
已经有5人回复











回复此楼